专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07858806B2 Crystal form of 5-hydroxy-1-methylhydantoin 有权
标题翻译：晶体形式的5-羟基-1-甲基乙内酰脲
公开(公告)号：US07858806B2
公开(公告)日：2010-12-28
申请号：US12498967
申请日：2009-07-07
申请人： Kaoru Okamoto , Naoharu Nishimura , Akira Ishii
发明人： Kaoru Okamoto , Naoharu Nishimura , Akira Ishii
IPC分类号： C07D233/80
CPC分类号： C07D233/72
摘要： Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency.
摘要翻译：常规的5-羟基-1-甲基乙内酰脲的I型晶体在其中保留相当量的纯化步骤中使用的有机溶剂。相反，在II型晶体中，其中残留的有机溶剂的量小于检测限。即，II型晶体基本上不含残留的有机溶剂。通过从水中重结晶获得的5-羟基-1-甲基乙内酰脲的新型II型晶体不仅基本上不含有残留的有机溶剂，而且还具有高的堆积密度，因此对于药物制剂是有利的。它们还具有有利于生产的性质，例如低粘附性。该晶体作为具有高度安全性的药物的材料，例如用于肾功能不全的药物是显着有用的。

2. 发明申请

US20090270634A1 NOVEL CRYSTAL FORM OF 5-HYDROXY-1-METHYLHYDANTOIN 有权
标题翻译： 5-羟基-1-甲基乙二胺的新晶体形式
公开(公告)号：US20090270634A1
公开(公告)日：2009-10-29
申请号：US12498967
申请日：2009-07-07
申请人： Kaoru Okamoto , Naoharu Nishimura , Akira Ishii
发明人： Kaoru Okamoto , Naoharu Nishimura , Akira Ishii
IPC分类号： C07D233/72
CPC分类号： C07D233/72
摘要： Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency.
摘要翻译：常规的5-羟基-1-甲基乙内酰脲的I型晶体在其中保留相当量的纯化步骤中使用的有机溶剂。相反，在II型晶体中，其中残留的有机溶剂的量小于检测限。即，II型晶体基本上不含残留的有机溶剂。通过从水中重结晶获得的5-羟基-1-甲基乙内酰脲的新型II型晶体不仅基本上不含有残留的有机溶剂，而且还具有高堆积密度，因此对于药物制剂是有利的。它们还具有有利于生产的性质，例如低粘附性。该晶体作为具有高度安全性的药物的材料，例如用于肾功能不全的药物是显着有用的。

3. 发明申请

US20050143437A1 Novel crystal form of 5-hydroxy-1-methylhydantoin 失效
标题翻译：新型晶体形式的5-羟基-1-甲基乙内酰脲
公开(公告)号：US20050143437A1
公开(公告)日：2005-06-30
申请号：US10508496
申请日：2003-04-09
申请人： Kaoru Okamoto , Naoharu Nishimura , Akira Ishii
发明人： Kaoru Okamoto , Naoharu Nishimura , Akira Ishii
IPC分类号： C07D233/66 , A61K31/4166 , A61P13/12 , C07D233/72
CPC分类号： C07D233/72
摘要： Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency.
摘要翻译：常规的5-羟基-1-甲基乙内酰脲的I型晶体在其中保留相当量的纯化步骤中使用的有机溶剂。相反，在II型晶体中，其中残留的有机溶剂的量小于检测限。即，II型晶体基本上不含残留的有机溶剂。通过从水中重结晶获得的5-羟基-1-甲基乙内酰脲的新型II型晶体不仅基本上不含有残留的有机溶剂，而且还具有高体积密度，因此对于药物制剂是有利的。它们还具有有利于生产的性质，例如低粘附性。该晶体作为具有高度安全性的药物的材料，例如用于肾功能不全的药物是显着有用的。

4. 发明授权

US07569701B2 Crystal form of 5-hydroxy-1-methylimidazolidin-2,4-dione 失效
标题翻译：晶体形式的5-羟基-1-甲基咪唑烷-2,4-二酮
公开(公告)号：US07569701B2
公开(公告)日：2009-08-04
申请号：US10508496
申请日：2003-04-09
申请人： Kaoru Okamoto , Naoharu Nishimura , Akira Ishii
发明人： Kaoru Okamoto , Naoharu Nishimura , Akira Ishii
IPC分类号： C07D233/80 , A61K31/4166
CPC分类号： C07D233/72
摘要： Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency.
摘要翻译：常规的5-羟基-1-甲基乙内酰脲的I型晶体在其中保留相当量的纯化步骤中使用的有机溶剂。相反，在II型晶体中，其中残留的有机溶剂的量小于检测限。即，II型晶体基本上不含残留的有机溶剂。通过从水中重结晶获得的5-羟基-1-甲基乙内酰脲的新型II型晶体不仅基本上不含有残留的有机溶剂，而且还具有高堆积密度，因此对于药物制剂是有利的。它们还具有有利于生产的性质，例如低粘附性。该晶体作为具有高度安全性的药物的材料，例如用于肾功能不全的药物是显着有用的。

5. 发明申请

US20060241163A1 Optically active (S)-hydantoin derivative 审中-公开
标题翻译：光活性（S） - 乙内酰脲衍生物
公开(公告)号：US20060241163A1
公开(公告)日：2006-10-26
申请号：US11110267
申请日：2005-04-20
申请人： Kaoru Okamoto , Akira Ishii , Nobuhisa Okukado , Hirohide Matsuura , Fujio Naka
发明人： Kaoru Okamoto , Akira Ishii , Nobuhisa Okukado , Hirohide Matsuura , Fujio Naka
IPC分类号： A61K31/4166
CPC分类号： A61K31/4166 , C07D233/66
摘要： (S)-(−)-5-hydroxy-1-methylhydantoin is useful as a drug having high safety. Since the compound of the present invention, (S)-(−)-5-hydroxy-1-methylhydantoin, rarely changes to the metabolite having high toxicity compared with the R-form and the racemate, it is preferred as an agent for renal failure especially when used for chronic renal insufficiency in a patient where toxic substances are not excreted, but are accumulated in the body due to disturbance of renal functions.
摘要翻译：（S） - （ - ） - 5-羟基-1-甲基乙内酰脲可用作高安全性的药物。由于本发明的化合物，与R型和外消旋体相比，（S） - （ - ） - 5-羟基-1-甲基乙内酰脲很少改变为毒性高的代谢物，因此优选作为肾脏剂特别是用于慢性肾功能不全的患者，其中有毒物质不会排泄，但由于肾功能障碍而累积在体内。

6. 发明申请

US20060241162A1 Optically active (R)-hydantoin derivative 审中-公开
标题翻译：光活性（R） - 乙内酰脲衍生物
公开(公告)号：US20060241162A1
公开(公告)日：2006-10-26
申请号：US11110111
申请日：2005-04-20
申请人： Kaoru Okamoto , Akira Ishii , Nobuhisa Okukado , Hirohide Matsuura , Mitsuru Naiki , Kazuyoshi Sawada
发明人： Kaoru Okamoto , Akira Ishii , Nobuhisa Okukado , Hirohide Matsuura , Mitsuru Naiki , Kazuyoshi Sawada
IPC分类号： A61K31/4166 , C07D233/04
CPC分类号： C07D233/66
摘要： (R)-(+)-5-hydroxy-1-methylhydantoin is an optically active substance having an excellent suppressive action of the progression of renal failure. At an administration to a model animal of renal failure, (R)-(+)-5-hydroxy-1-methylhydantoin significantly suppresses an increase of creatinine in blood as compared with the S-form and the racemate, and shows an excellent suppressive action to the progression of renal failure by improving creatinine clearance. Thus, (R)-(+)-5-hydroxy-1-methylhydantoin is useful as a highly-active agent for renal failure.
摘要翻译：（R） - （+） - 5-羟基-1-甲基乙内酰脲是具有优异的肾衰竭进展的抑制作用的光学活性物质。（R） - （+） - 5-羟基-1-甲基乙内酰脲在给予肾功能衰竭模型动物时，与S型和外消旋体相比显着抑制血液中肌酸酐的增加，显示出优异的抑制作用通过改善肌酐清除率来促进肾衰竭的进展。因此，（R） - （+） - 5-羟基-1-甲基乙内酰脲可用作肾功能衰竭的高活性剂。

7. 发明授权

US07848200B2 Method and apparatus of reproducing multilevel information 失效
标题翻译：再现多层次信息的方法和装置
公开(公告)号：US07848200B2
公开(公告)日：2010-12-07
申请号：US11624862
申请日：2007-01-19
申请人： Kaoru Okamoto , Jun Sumioka , Masakuni Yamamoto
发明人： Kaoru Okamoto , Jun Sumioka , Masakuni Yamamoto
IPC分类号： G11B20/10 , G11B27/36 , G11B5/09
CPC分类号： G11B20/20 , G11B20/10009
摘要： A method of reproducing multilevel information using a light spot. The multilevel information is recorded by defining virtual cells at regular intervals on tracks of an optical information recording medium and varying sizes of information pits in the cells. The method includes the steps of obtaining cell boundary values, each of the cell boundary values being obtained by performing sampling when the center of the light spot reaches a boundary between adjacent cells, calculating cell boundary value metrics on the basis of the cell boundary values and prestored reference values for the cell boundary values, calculating path metrics on the basis of the cell boundary value metrics, selecting a path metric having a minimum value of the path metrics, and reproducing the multilevel information on the basis of the path metric having the minimum value of the path metrics.
摘要翻译：使用光点再现多级信息的方法。通过在光信息记录介质的轨道上以规则的间隔定义虚拟单元并且在单元中定义不同大小的信息凹坑来记录多级信息。该方法包括以下步骤：获得单元格边界值，每个单元格边界值是通过当光点的中心到达相邻单元格之间的边界时执行采样而获得的，基于单元边界值计算单元边界值度量;以及预先存储的单元边界值的参考值，基于单元边界值度量计算路径度量，选择具有路径度量的最小值的路径度量，以及基于具有最小值的路径度量再现多级信息路径度量的值。

8. 发明申请

US20080013582A1 Semiconductor laser device and method of manufacturing the same 审中-公开
标题翻译：半导体激光器件及其制造方法
公开(公告)号：US20080013582A1
公开(公告)日：2008-01-17
申请号：US11708135
申请日：2007-02-20
申请人： Kaoru Okamoto , Ryu Washino , Kazuhiro Komatsu , Yasushi Sakuma
发明人： Kaoru Okamoto , Ryu Washino , Kazuhiro Komatsu , Yasushi Sakuma
IPC分类号： H01S5/026 , H01L33/00
CPC分类号： H01S5/12 , B82Y20/00 , H01S5/1231 , H01S5/125 , H01S5/34306 , H01S5/34313
摘要： A method of manufacturing semiconductor laser device capable of reducing κL, with manufacturing restrictions satisfied, is provided. In a distributed-feedback or distributed-reflective semiconductor laser device, immediately before burying regrowth of a diffraction grating, halogen-based gas is introduced to a reactor, and etching is performed on the diffraction grating so that each side wall has at least two or more crystal faces and a ratio of length of an upper side in a waveguide direction to a bottom side parallel to a (100) surface is 0 to 0.3. And, a reactive product formed on side surfaces of the diffraction grating and in trench portions between stripes of the diffraction grating at an increase of temperature for regrowth is removed. Therefore, the diffraction grating with reduced height and a sine wave shape is obtained, thereby κL of the device is reduced. Thus, an oscillation threshold and optical output efficiency can be improved.
摘要翻译：提供了一种制造能够减少kappa的半导体激光装置的方法，其制造限制被满足。在分布反馈或分布反射半导体激光器件中，在埋入衍射光栅的再生长之前，将卤素基气体引入反应器，并在衍射光栅上进行蚀刻，使得每个侧壁具有至少两个或更多的晶面和波导方向的上侧与平行于（100）面的底面的长度的比率为0〜0.3。并且，在再生长温度升高时，衍射光栅的侧面和衍射光栅的条纹之间的沟槽部分中形成的反应产物被去除。因此，获得具有降低的高度和正弦波形的衍射光栅，从而减小了器件的κ。因此，可以提高振荡阈值和光输出效率。

9. 发明申请

US20070171800A1 METHOD AND APPARATUS OF REPRODUCING MULTILEVEL INFORMATION 失效
标题翻译：复制多媒体信息的方法与装置
公开(公告)号：US20070171800A1
公开(公告)日：2007-07-26
申请号：US11624862
申请日：2007-01-19
申请人： Kaoru Okamoto , Jun Sumioka , Masakuni Yamamoto
发明人： Kaoru Okamoto , Jun Sumioka , Masakuni Yamamoto
IPC分类号： G11B20/10
CPC分类号： G11B20/20 , G11B20/10009
摘要： In a method of reproducing multilevel information, cell-boundary values are obtained. Each of the cell-boundary values is obtained when the center of a light spot comes at a boundary between adjacent cells. Then, on the basis of the cell-boundary values and prestored reference values for the cell-boundary value, cell-boundary-value metrics are calculated. Furthermore, on the basis of the cell-boundary-value metrics, path metrics are calculated.
摘要翻译：在再现多级信息的方法中，获得了单元格边界值。当光点的中心位于相邻单元之间的边界时，获得每个单元格边界值。然后，基于小区边界值和小区边界值的预存储参考值，计算小区边界值度量。此外，基于小区边界值度量，计算路径度量。

10. 发明申请

US20060222032A1 Optical semiconductor element, method of manufacturing optical semiconductor element and optical module 审中-公开
标题翻译：光半导体元件，光半导体元件及光模块的制造方法
公开(公告)号：US20060222032A1
公开(公告)日：2006-10-05
申请号：US11215122
申请日：2005-08-31
申请人： Yasushi Sakuma , Katsuya Motoda , Kaoru Okamoto , Ryu Washino
发明人： Yasushi Sakuma , Katsuya Motoda , Kaoru Okamoto , Ryu Washino
IPC分类号： H01S5/00
CPC分类号： H01S5/12 , H01S5/227 , H01S5/30
摘要： An InGaAsP thin film layer having the same index of refraction as a diffraction grating is inserted between a p-type InP clad layer and the diffraction grating composed of an InGaAsP layer. In this structure, the InGaAsP layer is present over an active layer, and the amount of thermal diffusion of dopant to the vicinity of the active layer does not depend on an aperture width or the presence or absence of the diffraction grating when the p-type InP clad layer is grown, thereby obtaining a stable optical output, a threshold current, and slope efficiency.
摘要翻译：将具有与衍射光栅相同折射率的InGaAsP薄膜层插入p型InP包层和由InGaAsP层构成的衍射光栅之间。在该结构中，InGaAsP层存在于有源层上，并且掺杂剂到有源层附近的热扩散量不依赖于孔径宽度或衍射光栅的存在或不存在，当p型生长InP覆层，从而获得稳定的光输出，阈值电流和斜率效率。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式